在那些历时4到8年之间的实验中,服用阿司匹林的患者因癌症而死亡的概率比那些服用安慰剂的患者小了21%。
These results were based on 674 cancer deaths, so are unlikely to represent the kind of statistical oddity that can beset studies on cancer risks that sometimes create headlines.
这些结果是在674例癌症死亡病例的基础上得出的,所以不大可能是所谓的统计学上的例外。对癌症风险的研究会因这种例外而受挫,有时甚至会闹成大资讯。
The benefits of aspirin were also apparent many years after the trials had ended.
试验结束后的很多年后,阿司匹林的效果也仍旧明显。
After five years, death rates for all cancers fell by 35% and for gastrointestinal cancers by 54%.
五年后,所有癌症的死亡率下降了35%,而胃肠道癌症的死亡率则下降了54%。
A long-term follow-up of patients showed that the 20-year risk of cancer death remained 20% lower in those who had taken aspirin.
一项长期的病情跟踪报告显示,那些服用阿司匹林的患者的20年内的癌症死亡风险比那些不服用的低了20%。
The study revealed that the effect takes time to accrue, so aspirin must be taken over a long period.
这项研究揭示了阿司匹林的效果是随着时间而递增的,所以必须长期服用才行。
【阿司匹林让人吃惊的另一面】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15